Artemether sublingual - LondonPharma

Drug Profile

Artemether sublingual - LondonPharma

Alternative Names: Artemether sublingual spray; ArTiMist; LON 002

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProtoPharma
  • Developer LondonPharma; ProtoPharma
  • Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Fluorenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Falciparum malaria
  • Phase I/II Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours in Africa (Sublingual, Spray)
  • 06 Aug 2015 Malaria Research Company is still in the process of preparing the regulatory dossier to support filings for Falciparum malaria in Rwanda, Ghana and Burkina Faso
  • 19 Dec 2014 Preclinical trials in Cancer in United Kingdom (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top